AbbVie today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety…
Roche announced that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the…
Neumora Therapeutics, a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and CEO. “I am excited to welcome…
AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results. PRODUODOPA is the first-and-only…
Voyager Therapeutics, a biotech company dedicated to advancing neurogenetic medicines, announced a strategic collaboration and capsid license agreement with Novartis Pharma, a subsidiary of Novartis to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will provide…
Bristol Myers Squibb and Karuna Therapeutics announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for a total equity value of $14.0 billion, or $12.7 billion net of estimated…
AbbVie and Cerevel Therapeutics announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders. The…